Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

Inclusion Criteria:

• Patients over 18 years of age with HIV infection who have never receivedantiretroviral treatment with Rilpivirine.

• Have a stable ART pattern for at least the last 6 month

Exclusion Criteria:

• Not having received more than three previous lines of antiretroviral treatment

• No resistance mutations that compromise the efficacy of Rilpivirine, Dolutegravir,Tenofovir (TDF and/or TAF) or Emtricitabine.

• Have an HIV viral load < 50 copies/ml for at least the last 6 months, 1 blip below 500 copies/ml is allowed during this period.

• Have an ultrasound-diagnosed fatty liver metabolic disease or a CAP (ControlledAttenuation Parameter®) measurement > 238 dB/m with an IQR < 30 dB/m.

• Have an fatty liver metabolic disease with some degree of fibrosis diagnosed by ET (Fibroscan®) > 5.2 kPa. In patients in whom ET is not possible, have a FIB-4 >1.3.

• Be able to understand and comply with the requirements and instructions of theprotocol.

• Understanding long-term commitment to study

• Acceptance of their participation in the study by signing an informed consent form.

Exclusion Criteria:

• Have chronic HBV infection (presence of HBsAg+) or HCV (detectable HCV viral load).Patients with past treated HCV are also not allowed to be included (does not includepatients with spontaneously resolved HCV infection).

• Have diabetes mellitus on treatment with SGLT2, GLP1 or plioglitazone of less than 6months duration.

• Have a history of alcohol abuse

• Harmful alcohol consumption, defined as >30 grams of alcohol per day in men and >20grams of alcohol per day in women.

• Have chronic decompensated liver disease, defined as any of the following: presenceof encephalopathy, ascites, coagulopathy, oesophageal or gastric varices, orpersistent jaundice.

• Any previous physical or mental condition (such as habitual drug use) that theinvestigator believes may interfere with the patient's ability to comply with thestudy protocol.

• Pregnancy or breastfeeding at the screening visit or at any time during the study orintention to become pregnant during the study period.

• Prior history of Rilpivirine use of any duration.